To Estimate the Efficacy of Treatment With TNFi as Monotherapy or Combination Therapy With MTX and Compare and Contrast Efficacy With Tofacitinib as Monotherapy and Combination Therapy in a Real World Setting.
Status
Completed
Conditions
Rheumatoid Arthritis
Treatments
Other: patterns of use of combination therapy and monotherapy
Details and patient eligibility
About
To estimate the efficacy of treatment with TNFi as monotherapy or combination therapy with MTX and compare and contrast efficacy with Tofacitinib as monotherapy and combination therapy in a real world setting.
Enrollment
9,159 patients
Sex
All
Volunteers
No Healthy Volunteers
Inclusion criteria
- RA patients in Corrona initiating a TNFi biologic (adalimumab, etanercept, infliximab, golimumab, certolizumab pegol) during follow-up in Corrona with no prior use of Tofacitinib
Exclusion criteria
- Patients with no history of cDMARD but history of 1+ biologics - these cases will be excluded from analyses
- Patients using combination therapy with a cDMARD other than MTX will be excluded
- Patients using combination therapy of MTX and another cDMARD will be excluded
Trial design
9,159 participants in 3 patient groups
All TNFi initiations
Treatment:
Other: patterns of use of combination therapy and monotherapy
TNFi initiations after 11/6/2012 for comparisons with Tofacitinib initiators
Treatment:
Other: patterns of use of combination therapy and monotherapy
RA patient in Corrona with initiation Tofacitinib during follow-up in Corron
Treatment:
Other: patterns of use of combination therapy and monotherapy
Trial contacts and locations
1
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal
© Copyright 2026 Veeva Systems